MannKind's FUROSCIX ReadyFlow: A 10-Second Catalyst the Market is Missing

Related Articles

Alibaba's AI Bet: Why the Market is Missing a 58% Upside

1 months ago

SoundHound AI's Agentic Bet: Why the Market is Missing the Transactional Upside

2 months ago

Did MannKind's Q1 2026 Earnings Report Signal a Turning Point

4 months ago

NVIDIA's $50 Trillion Physical AI Bet: Why the Market is Missing the Next "ChatGPT Moment"

1 months ago

Category

You may also like

Stock News•2 weeks ago

Liquidia: A Linear Launch Priced For Exponential Growth

Liquidia's YUTREPIA growth is decelerating, with prescriber acquisition halved and launch tailwinds fading, against a $6B+ valuation. Future expansion faces community-penetration hurdles and structura...

LQDA

Share

Stock News•1 months ago

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

MannKind received FDA approval for Furoscix ReadyFlow, the first autoinjector delivering IV-equivalent diuretic therapy for edema in adults with heart failure or chronic kidney disease.

MNKD

Share

Stock News•1 months ago

Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk

MannKind insider sold 65,808 shares (~$269K), representing 6% of direct holdings. The sale is overshadowed by a 9% royalty stream at risk.

MNKD

Share